Call it a week of second chances. Multiple biotechs breathed new life into drugs sorely in need of it. Sage Therapeutics proved a drug that had failed a trial a rare form of epilepsy could be the first ever approved therapy for postpartum depression. Otonomy, reviving a hearing loss drug thought to be on the […]
Original Article: Bio Roundup: Barron Joins GSK, Sage Bounces Back, Valeant Dumps Addyi
NEXT ARTICLE